0001193125-26-221624
SEC filingMyomo, Inc. appointed Joseph M. Manko Jr. to its Board of Directors effective May 9, 2026, as a Class I director serving until the 2027 annual meeting; he is a significant shareholder and experienced med-tech investor with deep capital markets and governance expertise.
The appointment of Joseph M. Manko Jr. to Myomo’s Board reflects a strategic reinforcement of governance and capital markets expertise amid the company’s growth phase. As founder and Senior Principal of Horton Capital Management LLC—a significant shareholder—Mr. Manko’s alignment with long-term shareholder interests is explicit. His background spans senior roles at Deutsche Bank, Merrill Lynch, and BZ Fund Management, along with board service at Safeguard Scientifics (where he serves as Chairman) and KORU Medical Systems, underscoring domain-relevant experience in med-tech and life sciences. While he is not assigned to any board committee at this time, his stated focus on supporting Myomo’s 'Success Pillars for 2026 and beyond'—including growth strategy, patient access, and shareholder value creation—signals an active governance role. Compensation terms are standardized for non-employee directors, with no special arrangements disclosed. Given the absence of financial disclosures, executive leadership changes, or material agreements in this filing, the event carries medium materiality: it strengthens board composition and investor confidence but does not alter near-term operational or financial trajectory.